董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Prahlad Singh President and Chief Executive Officer and Director 60 1192.66万美元 10.63 2025-10-23
Michel Vounatsos Director 63 32.99万美元 0.93 2025-10-23
Samuel R. Chapin Director 67 33.99万美元 1.80 2025-10-23
Michael A. Klobuchar Director 49 35.74万美元 0.27 2025-10-23
Michelle McMurry Heath Director 55 31.49万美元 0.30 2025-10-23
Alexis P. Michas Non-Executive Chair 67 45.00万美元 4.26 2025-10-23
Frank Witney Director 71 31.99万美元 1.87 2025-10-23
Sophie V. Vandebroek Director 63 36.24万美元 0.27 2025-10-23
Peter Barrett Director 72 33.49万美元 2.36 2025-10-23
Pascale Witz Director 58 31.49万美元 1.13 2025-10-23

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Prahlad Singh President and Chief Executive Officer and Director 60 1192.66万美元 10.63 2025-10-23
Tajinder Vohra Senior Vice President, Global Operations 59 230.94万美元 2.26 2025-10-23
Miriame Victor Senior Vice President, Chief Commercial Officer 44 247.76万美元 1.43 2025-10-23
Maxwell Krakowiak Senior Vice President and Chief Financial Officer 35 324.57万美元 2.34 2025-10-23
Anita Gonzales Vice President and Chief Accounting Officer 49 未披露 未持股 2025-10-23
Joel S. Goldberg Senior Vice President, Administration, General Counsel and Secretary 56 338.16万美元 3.77 2025-10-23

董事简历

中英对照 |  中文 |  英文
Prahlad Singh

Prahlad Singh于2019年12月30日当选为PerkinElmer的总裁兼首席执行官,并于2019年间被任命为Perkinellmer股份有限公司的董事会成员。此前,Singh博士自2019年1月起担任Perkinellmer 的总裁和首席运营官。Singh博士于2014年5月加入Perkineller,担任股份有限公司诊断业务的总裁。他于2016年9月当选为高级副总裁,并于2018年3月当选为执行副总裁。在加入PerkinElmer之前,Singh博士于2012年至2014年担任GE Healthcare女性健康业务总经理,负责其乳房X光摄影和骨密度测量业务。在此之前,Singh博士曾在GE Healthcare和Philips Healthcar担任战略、业务发展和并购方面的高级执行官。在其职业生涯早期,他曾在杜邦制药公司担任领导职务,并在随后的百时美施贵宝医疗成像公司(Bristol Myers Squibb Medical Imaging)担任领导职务。该公司负责管理亚太和中东地区。Singh 博士拥有密苏里哥伦比亚大学化学博士学位和东北大学工商管理硕士学位。他的研究工作已获得多项专利,并在同行评议的期刊上发表。


Prahlad Singh,is currently the President and Chief Executive Officer of Revvity, Inc. (which was previously affiliated with PerkinElmer, Inc.). He was promoted to President and Chief Executive Officer effective December 30, 2019 and was appointed to its Board of Directors in August 2019. Prior to his current role, he held various senior executive operating positions within PerkinElmer. Prior to joining PerkinElmer in 2014, Mr. Singh was a General Manager at GE Healthcare, and before that, Mr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently at Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East regions.In addition to his public board service, Mr. Singh also serves on the Board of the Analytical, Life Science & Diagnostics Association.Mr. Singh holds a BS degree from Wilson College, Mumbai, India, a PhD in chemistry from the University of Missouri-Columbia and an MBA from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals.
Prahlad Singh于2019年12月30日当选为PerkinElmer的总裁兼首席执行官,并于2019年间被任命为Perkinellmer股份有限公司的董事会成员。此前,Singh博士自2019年1月起担任Perkinellmer 的总裁和首席运营官。Singh博士于2014年5月加入Perkineller,担任股份有限公司诊断业务的总裁。他于2016年9月当选为高级副总裁,并于2018年3月当选为执行副总裁。在加入PerkinElmer之前,Singh博士于2012年至2014年担任GE Healthcare女性健康业务总经理,负责其乳房X光摄影和骨密度测量业务。在此之前,Singh博士曾在GE Healthcare和Philips Healthcar担任战略、业务发展和并购方面的高级执行官。在其职业生涯早期,他曾在杜邦制药公司担任领导职务,并在随后的百时美施贵宝医疗成像公司(Bristol Myers Squibb Medical Imaging)担任领导职务。该公司负责管理亚太和中东地区。Singh 博士拥有密苏里哥伦比亚大学化学博士学位和东北大学工商管理硕士学位。他的研究工作已获得多项专利,并在同行评议的期刊上发表。
Prahlad Singh,is currently the President and Chief Executive Officer of Revvity, Inc. (which was previously affiliated with PerkinElmer, Inc.). He was promoted to President and Chief Executive Officer effective December 30, 2019 and was appointed to its Board of Directors in August 2019. Prior to his current role, he held various senior executive operating positions within PerkinElmer. Prior to joining PerkinElmer in 2014, Mr. Singh was a General Manager at GE Healthcare, and before that, Mr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently at Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East regions.In addition to his public board service, Mr. Singh also serves on the Board of the Analytical, Life Science & Diagnostics Association.Mr. Singh holds a BS degree from Wilson College, Mumbai, India, a PhD in chemistry from the University of Missouri-Columbia and an MBA from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals.
Michel Vounatsos

Michel Vounatsos,2017年1月以来,他一直担任首席执行官。从2016年4月到2016年12月,他担任执行副总裁兼首席商业官。加入Biogen公司之前,他曾任职Merck公司20年,在那里他最近担任总裁,负责初级保健、客户业务线。他曾领导Merck公司全球初级保健业务单元,包含Merck公司的心脏代谢、全科医学、妇女健康和生物仿制制药集团,也曾开发和制定一个战略框架加强公司的关键关系,其中包括最重要的供应商、纳税人、零售商、世界上最大的政府。他此前曾担任Merck公司的欧洲和中国领导职务。此前,他曾担任Ciba-Geigy公司的管理职务。他曾就读于Universite Victor Segalen, Bordeaux II, France, C.S.C.T.。他拥有医学证书,以及HEC School of Management - Paris的工商管理硕士学位。于2023年1月7日委任为再鼎医药有限公司独立董事。


Michel Vounatsos,In addition to serving on Board, he has also served on other public company boards, including Revvity, Inc. (NYSE) since 2020. He also serves on the advisory board of Tsinghua University School of Pharmaceutical Sciences in Beijing, China and as Chairman of the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux.Previously, Mr. Vounatsos served as Chief Executive Officer and member of the Board of Directors of Biogen, Inc. (Nasdaq) from 2017 to 2022, after serving as Executive Vice President and Chief Commercial Officer in 2016. Prior to joining Biogen, Mr. Vounatsos held various roles of increasing responsibility at Merck & Co. from 1996 to 2016, including President of Primary Care and Merck Customer Centricity, President of MSD China, and other leadership positions across Europe. In these positions, he was responsible for strategic and business development decisions, led several strategic alliances, and helped the business grow and significantly increase performance.Mr. Vounatsos received an MBA from HEC School of Management in Paris, France and a C.S.C.T. (Certificate of Clinical and Therapeutic Synthesis) in Medicine from Université Victor Segalen, Bourdeaux II, France.
Michel Vounatsos,2017年1月以来,他一直担任首席执行官。从2016年4月到2016年12月,他担任执行副总裁兼首席商业官。加入Biogen公司之前,他曾任职Merck公司20年,在那里他最近担任总裁,负责初级保健、客户业务线。他曾领导Merck公司全球初级保健业务单元,包含Merck公司的心脏代谢、全科医学、妇女健康和生物仿制制药集团,也曾开发和制定一个战略框架加强公司的关键关系,其中包括最重要的供应商、纳税人、零售商、世界上最大的政府。他此前曾担任Merck公司的欧洲和中国领导职务。此前,他曾担任Ciba-Geigy公司的管理职务。他曾就读于Universite Victor Segalen, Bordeaux II, France, C.S.C.T.。他拥有医学证书,以及HEC School of Management - Paris的工商管理硕士学位。于2023年1月7日委任为再鼎医药有限公司独立董事。
Michel Vounatsos,In addition to serving on Board, he has also served on other public company boards, including Revvity, Inc. (NYSE) since 2020. He also serves on the advisory board of Tsinghua University School of Pharmaceutical Sciences in Beijing, China and as Chairman of the Supervisory Board of Liryc, the Electrophysiology and Heart Modeling Institute at the University of Bordeaux.Previously, Mr. Vounatsos served as Chief Executive Officer and member of the Board of Directors of Biogen, Inc. (Nasdaq) from 2017 to 2022, after serving as Executive Vice President and Chief Commercial Officer in 2016. Prior to joining Biogen, Mr. Vounatsos held various roles of increasing responsibility at Merck & Co. from 1996 to 2016, including President of Primary Care and Merck Customer Centricity, President of MSD China, and other leadership positions across Europe. In these positions, he was responsible for strategic and business development decisions, led several strategic alliances, and helped the business grow and significantly increase performance.Mr. Vounatsos received an MBA from HEC School of Management in Paris, France and a C.S.C.T. (Certificate of Clinical and Therapeutic Synthesis) in Medicine from Université Victor Segalen, Bourdeaux II, France.
Samuel R. Chapin

Samuel R. Chapin, 2016年从美国银行美林(Bank of America Merrill Lynch)退休,担任全球企业和投资银行业务执行副董事长,此前他在投资银行工作了30多年。2010年至2016年,他担任执行副董事长,负责管理与公司一些最大客户的关系。Chapin先生曾从事过总额超过5000亿美元的广泛融资和战略咨询任务,并被《投资交易商文摘》(Investment Dealers’Digest)评为年度投资银行家。他于2003年被任命为Merrill Lynch & Co., Inc.的副董事长,也是该公司执行运营委员会的成员。他曾在Bank of America Merrill Lynch担任许多其他高级领导职务,包括负责全球投资银行部门和管理公司的许多全球企业关系。Chapin先生自2019年以来一直担任Rockefeller Capital Management(一家领先的独立私人金融服务公司)的高级顾问,他也是O-I Glass, Inc.和PHINIA, Inc.的董事会成员,这两家公司都是上市公司,并且曾担任CIRCOR International, Inc.的董事,直到2023年。此外,他还担任Lafayette College的名誉董事和New York’s Roundabout Theatre Company的名誉董事。Chapin先生持有Lafayette College的文学学士学位和The Wharton School at The University of Pennsylvania的工商管理硕士学位。


Samuel R. Chapin,retired in 2016 as Executive Vice Chairman of Bank of America Merrill Lynch, a multinational investment bank, after more than 30 years in banking. He served as Executive Vice Chairman of Bank of America Merrill Lynch from 2010 until 2016, during which time he was responsible for managing relationships with a number of the firm's largest corporate clients. Mr. Chapin joined Merrill Lynch in 1984 as a member of the Mergers and Acquisitions group and was named a Managing Director in Investment Banking in 1993, Senior Vice President and head of Merrill Lynch's global investment banking division in 2001 and Vice Chairman in 2003. He currently serves on the boards of PHINIA Inc. and Revvity, Inc. (formerly PerkinElmer, Inc.), chairing Revvity's audit committee, and is also an emeritus member of the Board of Trustees at Lafayette College. Mr. Chapin previously served as a member of the board of directors of Circor International, Inc. from January 2019 to June 2023 and chaired its audit committee. Mr. Chapin holds a B.A. in economics from Lafayette College and an M.B.A. from the Wharton School at the University of Pennsylvania.
Samuel R. Chapin, 2016年从美国银行美林(Bank of America Merrill Lynch)退休,担任全球企业和投资银行业务执行副董事长,此前他在投资银行工作了30多年。2010年至2016年,他担任执行副董事长,负责管理与公司一些最大客户的关系。Chapin先生曾从事过总额超过5000亿美元的广泛融资和战略咨询任务,并被《投资交易商文摘》(Investment Dealers’Digest)评为年度投资银行家。他于2003年被任命为Merrill Lynch & Co., Inc.的副董事长,也是该公司执行运营委员会的成员。他曾在Bank of America Merrill Lynch担任许多其他高级领导职务,包括负责全球投资银行部门和管理公司的许多全球企业关系。Chapin先生自2019年以来一直担任Rockefeller Capital Management(一家领先的独立私人金融服务公司)的高级顾问,他也是O-I Glass, Inc.和PHINIA, Inc.的董事会成员,这两家公司都是上市公司,并且曾担任CIRCOR International, Inc.的董事,直到2023年。此外,他还担任Lafayette College的名誉董事和New York’s Roundabout Theatre Company的名誉董事。Chapin先生持有Lafayette College的文学学士学位和The Wharton School at The University of Pennsylvania的工商管理硕士学位。
Samuel R. Chapin,retired in 2016 as Executive Vice Chairman of Bank of America Merrill Lynch, a multinational investment bank, after more than 30 years in banking. He served as Executive Vice Chairman of Bank of America Merrill Lynch from 2010 until 2016, during which time he was responsible for managing relationships with a number of the firm's largest corporate clients. Mr. Chapin joined Merrill Lynch in 1984 as a member of the Mergers and Acquisitions group and was named a Managing Director in Investment Banking in 1993, Senior Vice President and head of Merrill Lynch's global investment banking division in 2001 and Vice Chairman in 2003. He currently serves on the boards of PHINIA Inc. and Revvity, Inc. (formerly PerkinElmer, Inc.), chairing Revvity's audit committee, and is also an emeritus member of the Board of Trustees at Lafayette College. Mr. Chapin previously served as a member of the board of directors of Circor International, Inc. from January 2019 to June 2023 and chaired its audit committee. Mr. Chapin holds a B.A. in economics from Lafayette College and an M.B.A. from the Wharton School at the University of Pennsylvania.
Michael A. Klobuchar

Michael A. Klobuchar,自2021年起担任Merck(一家领先的研究密集型全球生物制药公司)的执行副总裁兼首席战略官,也是Merck执行委员会的成员。在此职位上,他领导Merck战略的推进和执行,并负责业务发展和信息技术。在此之前,他于2019年至2021年担任Merck研究实验室(该公司的研发组织)的高级副总裁、首席财务官兼投资组合和联盟管理主管,并领导该组织内的全球投资组合和联盟管理团队。Klobuchar先生于1998年加入Merck研究实验室,并在公司的研究、制造、商业规划、财务和战略组织中担任过各种职位,责任越来越大,包括在两家公司合并后,领导与研究Merck实验室与先灵葆雅研发整合相关的关键要素。他持有Villanova University的工商管理硕士学位,Rutgers University的化学工程理学硕士学位和Purdue University的理学学士学位。


Michael A. Klobuchar,joined Eikon Therapeutics in 2024, and oversees the company's corporate infrastructure, including global supply chain management and product manufacturing. Mr. Klobuchar is a member of Eikon's Executive Committee and manages key executives across a variety of functional areas and business operations. Prior to joining Eikon, Mr. Klobuchar had been associated with Merck & Co., Inc., a premier research-intensive global biopharmaceutical company, for over 25 years, most recently serving from 2021 to 2024 as Executive Vice President and Chief Strategy Officer, and from 2019 to 2021 as Senior Vice President, CFO and Head of Portfolio and Alliance Management for Merck Research Laboratories. Prior to that, Mr. Klobuchar held a variety of positions of increasing responsibility in Merck's research, manufacturing, commercial planning, finance and strategy organizations, including leading key elements related to the integration of Merck Research Laboratories with Schering-Plough R&D following the merger of the two companies. Mr. Klobuchar received his Master of Business Administration degree from Villanova University, a Master of Science degree in chemical engineering from Rutgers University and a Bachelor of Science degree from Purdue University.
Michael A. Klobuchar,自2021年起担任Merck(一家领先的研究密集型全球生物制药公司)的执行副总裁兼首席战略官,也是Merck执行委员会的成员。在此职位上,他领导Merck战略的推进和执行,并负责业务发展和信息技术。在此之前,他于2019年至2021年担任Merck研究实验室(该公司的研发组织)的高级副总裁、首席财务官兼投资组合和联盟管理主管,并领导该组织内的全球投资组合和联盟管理团队。Klobuchar先生于1998年加入Merck研究实验室,并在公司的研究、制造、商业规划、财务和战略组织中担任过各种职位,责任越来越大,包括在两家公司合并后,领导与研究Merck实验室与先灵葆雅研发整合相关的关键要素。他持有Villanova University的工商管理硕士学位,Rutgers University的化学工程理学硕士学位和Purdue University的理学学士学位。
Michael A. Klobuchar,joined Eikon Therapeutics in 2024, and oversees the company's corporate infrastructure, including global supply chain management and product manufacturing. Mr. Klobuchar is a member of Eikon's Executive Committee and manages key executives across a variety of functional areas and business operations. Prior to joining Eikon, Mr. Klobuchar had been associated with Merck & Co., Inc., a premier research-intensive global biopharmaceutical company, for over 25 years, most recently serving from 2021 to 2024 as Executive Vice President and Chief Strategy Officer, and from 2019 to 2021 as Senior Vice President, CFO and Head of Portfolio and Alliance Management for Merck Research Laboratories. Prior to that, Mr. Klobuchar held a variety of positions of increasing responsibility in Merck's research, manufacturing, commercial planning, finance and strategy organizations, including leading key elements related to the integration of Merck Research Laboratories with Schering-Plough R&D following the merger of the two companies. Mr. Klobuchar received his Master of Business Administration degree from Villanova University, a Master of Science degree in chemical engineering from Rutgers University and a Bachelor of Science degree from Purdue University.
Michelle McMurry Heath

Michelle Mcmurry Heath于2020年至2022年担任全球最大的生物技术倡导团体生物技术创新组织(Biotechnology Innovation Organization)的总裁兼首席执行官。2014年至2020年,McMurry Health博士曾在强生公司任职,担任医疗器械公司证据生成全球负责人,然后担任全球外部创新副总裁和监管科学全球领导者。在J&J任职之前,McMurry Health博士也是政府的关键科学政策领导人,对国家科学基金会的政策、计划和人员进行了全面分析。随后,奥巴马总统任命她为美国食品和药物管理局设备和放射健康中心的副科学主任。McMurry Health博士是阿斯彭研究所健康、生物医学科学和社会政策项目的创始主任,并从Robert Wood Johnson Foundation接受了科学政策方面的早期培训。McMurry Health博士还担任上市公司Bioventus的董事会成员。她在哈佛大学获得了生物化学文学士学位,在杜克大学医学科学家培训项目获得了博士/博士学位,成为第一位从这一著名项目毕业的非裔美国人,在担任政府和行业的政策和领导角色之前,她在研究团队工作了12年。


Michelle McMurry Heath,a medical doctor and molecular immunologist by training, has served as the Chief Executive Officer of BioTechquity Clinical, a novel clinical research organization designed to help drug and device innovators enroll and conduct diverse clinical trials, since founding the firm in 2024. Prior to her current position, Dr. McMurry-Heath was a consultant to the biotechnology industry and most recently served as President and Chief Executive Officer of the Biotechnology Innovation Organization, the world's largest biotechnology advocacy group, from 2020 to 2022. Dr. McMurry-Health was also previously with Johnson & Johnson (J&J) from 2014 to 2020, where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. Before joining J&J, Dr. McMurry-Heath was also a key science policy leader in government, conducting a comprehensive analysis of the National Science Foundation's policies, programs and personnel. President Obama then named her associate science director of the FDA's Center for Devices and Radiological Health.Dr. McMurry-Heath was the founding director of the Aspen Institute's Health, Biomedical Science, and Society Policy Program and received her early training in science policy from the Robert Wood Johnson Foundation. Dr. McMurry-Heath also serves on the board of directors at publicly traded Bioventus Inc. She received her Bachelor of Arts degree in biochemistry from Harvard University and her MD/PhD from Duke's Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program.
Michelle Mcmurry Heath于2020年至2022年担任全球最大的生物技术倡导团体生物技术创新组织(Biotechnology Innovation Organization)的总裁兼首席执行官。2014年至2020年,McMurry Health博士曾在强生公司任职,担任医疗器械公司证据生成全球负责人,然后担任全球外部创新副总裁和监管科学全球领导者。在J&J任职之前,McMurry Health博士也是政府的关键科学政策领导人,对国家科学基金会的政策、计划和人员进行了全面分析。随后,奥巴马总统任命她为美国食品和药物管理局设备和放射健康中心的副科学主任。McMurry Health博士是阿斯彭研究所健康、生物医学科学和社会政策项目的创始主任,并从Robert Wood Johnson Foundation接受了科学政策方面的早期培训。McMurry Health博士还担任上市公司Bioventus的董事会成员。她在哈佛大学获得了生物化学文学士学位,在杜克大学医学科学家培训项目获得了博士/博士学位,成为第一位从这一著名项目毕业的非裔美国人,在担任政府和行业的政策和领导角色之前,她在研究团队工作了12年。
Michelle McMurry Heath,a medical doctor and molecular immunologist by training, has served as the Chief Executive Officer of BioTechquity Clinical, a novel clinical research organization designed to help drug and device innovators enroll and conduct diverse clinical trials, since founding the firm in 2024. Prior to her current position, Dr. McMurry-Heath was a consultant to the biotechnology industry and most recently served as President and Chief Executive Officer of the Biotechnology Innovation Organization, the world's largest biotechnology advocacy group, from 2020 to 2022. Dr. McMurry-Health was also previously with Johnson & Johnson (J&J) from 2014 to 2020, where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. Before joining J&J, Dr. McMurry-Heath was also a key science policy leader in government, conducting a comprehensive analysis of the National Science Foundation's policies, programs and personnel. President Obama then named her associate science director of the FDA's Center for Devices and Radiological Health.Dr. McMurry-Heath was the founding director of the Aspen Institute's Health, Biomedical Science, and Society Policy Program and received her early training in science policy from the Robert Wood Johnson Foundation. Dr. McMurry-Heath also serves on the board of directors at publicly traded Bioventus Inc. She received her Bachelor of Arts degree in biochemistry from Harvard University and her MD/PhD from Duke's Medical Scientist Training Program, becoming the first African American to graduate from the prestigious program.
Alexis P. Michas

Alexis P. Michas,他是Juniper Investment Company, LLC的创始人和管理合伙人(2008年以来)。Juniper也是Aetolian Investors, LLC(一家注册商品池运营商)的负责人。他持有Harvard College的文学学士学位和Harvard Business School的工商管理硕士学位。他是博格华纳公司(BorgWarner Inc.)董事会的非执行主席和AstroNova, Inc.的董事会成员,这两家公司都是上市公司。他也是Atlantic Investment Management, Inc.(私人持有的投资公司)管理的基金的董事,以及私人持有的Theragenics Corporation的董事会成员。他还担任Lincoln Educational Services Corporation董事会的非执行主席(直到2015年),以及Allied Motion Technologies, Inc.的董事(直到2017年7月)。Michas于2019年12月30日被任命为董事会非执行主席。


Alexis P. Michas,is the founder and has been Managing Partner of Juniper Investment Company, LLC since 2008. Juniper is also a Principal of Aetolian Investors, LLC, a registered commodity pool operator. Mr. Michas received a Bachelor of Arts degree from Harvard College and a Master of Business Administration degree from Harvard Business School. Mr. Michas is the Non-Executive Chairman of the board of BorgWarner Inc. and a board member of AstroNova, Inc., both of which are publicly traded. Mr. Michas is also a director of funds managed by Atlantic Investment Management, Inc., a privately held investment company, as well as a board member of privately held Theragenics Corporation. Mr. Michas also served as the Non-Executive Chairman of the board of Lincoln Educational Services Corporation until 2015, and as a director of Allied Motion Technologies, Inc. until July 2017.
Alexis P. Michas,他是Juniper Investment Company, LLC的创始人和管理合伙人(2008年以来)。Juniper也是Aetolian Investors, LLC(一家注册商品池运营商)的负责人。他持有Harvard College的文学学士学位和Harvard Business School的工商管理硕士学位。他是博格华纳公司(BorgWarner Inc.)董事会的非执行主席和AstroNova, Inc.的董事会成员,这两家公司都是上市公司。他也是Atlantic Investment Management, Inc.(私人持有的投资公司)管理的基金的董事,以及私人持有的Theragenics Corporation的董事会成员。他还担任Lincoln Educational Services Corporation董事会的非执行主席(直到2015年),以及Allied Motion Technologies, Inc.的董事(直到2017年7月)。Michas于2019年12月30日被任命为董事会非执行主席。
Alexis P. Michas,is the founder and has been Managing Partner of Juniper Investment Company, LLC since 2008. Juniper is also a Principal of Aetolian Investors, LLC, a registered commodity pool operator. Mr. Michas received a Bachelor of Arts degree from Harvard College and a Master of Business Administration degree from Harvard Business School. Mr. Michas is the Non-Executive Chairman of the board of BorgWarner Inc. and a board member of AstroNova, Inc., both of which are publicly traded. Mr. Michas is also a director of funds managed by Atlantic Investment Management, Inc., a privately held investment company, as well as a board member of privately held Theragenics Corporation. Mr. Michas also served as the Non-Executive Chairman of the board of Lincoln Educational Services Corporation until 2015, and as a director of Allied Motion Technologies, Inc. until July 2017.
Frank Witney

Frank Witney,博士,曾担任总裁,2011年7月以来首席执行官和董事。卡梅隆博士担任总裁兼首席执行官Dionex公司从2009年4月到2011年5月。2008年12月至2009年4月,卡梅隆博士担任执行副总裁兼首席商务官。此前,从2002年7月到2008年12月,卡梅隆博士担任Panomics公司的总裁兼首席执行官。卡梅隆博士Cerus公司的董事会成员。


Frank Witney,most recently served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market-leading ion and high-performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix as Executive Vice President and Chief Commercial Officer when it acquired Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer. He previously held the role of President of Revvity's Drug Discovery Tools division following Revvity's acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as well as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation and Standard BioTools, Inc., as well as several privately held companies, and until 2024 was a director of Telesis Bio, Inc. (formerly known as Codex DNA). Dr. Witney is an Operating Partner at Ampersand Capital Partners.
Frank Witney,博士,曾担任总裁,2011年7月以来首席执行官和董事。卡梅隆博士担任总裁兼首席执行官Dionex公司从2009年4月到2011年5月。2008年12月至2009年4月,卡梅隆博士担任执行副总裁兼首席商务官。此前,从2002年7月到2008年12月,卡梅隆博士担任Panomics公司的总裁兼首席执行官。卡梅隆博士Cerus公司的董事会成员。
Frank Witney,most recently served as President and Chief Executive Officer of Affymetrix, Inc., which specialized in microarray technology and cellular analysis, from 2011 through March 2016 when it was acquired by Thermo Fisher Scientific Inc. Previously, Dr. Witney was President and Chief Executive Officer of Dionex Corp., a market-leading ion and high-performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix as Executive Vice President and Chief Commercial Officer when it acquired Panomics, Inc., a quantitative biology company, which Dr. Witney had led as President and Chief Executive Officer. He previously held the role of President of Revvity's Drug Discovery Tools division following Revvity's acquisition of Packard BioScience in 2001, where he served as President and Chief Operating Officer. Dr. Witney also held several positions at Bio-Rad Laboratories, leading that company's efforts to enter the proteomic and bioassay technologies market. Dr. Witney was a post-doctoral fellow at the National Institutes of Health and holds a PhD in molecular and cell biology and a Master of Science degree in microbiology from Indiana University, as well as a Bachelor of Science degree in microbiology from the University of Illinois. Dr. Witney is a member of the board of directors of publicly traded Cerus Corporation and Standard BioTools, Inc., as well as several privately held companies, and until 2024 was a director of Telesis Bio, Inc. (formerly known as Codex DNA). Dr. Witney is an Operating Partner at Ampersand Capital Partners.
Sophie V. Vandebroek

Sophie V. Vandebroek,自2021年起担任Strategic Vision Ventures, LLC(技术咨询公司)的创始人和所有者。此前,Vandebroek博士是麻省理工学院工程学院2019-2020学年的首任访问学者;2018年至2019年担任IBM新兴技术合作伙伴副总裁;2017年至2018年担任IBM研究院首席运营官。在加入IBM之前,她是Xerox Corporation的高管,在那里她的角色包括担任Xerox Corporation的首席技术官和公司副总裁,Xerox Innovation Group总裁和首席工程师。她还负责监督施乐公司的全球研究中心,包括帕洛阿尔托研究中心(PARC Inc.)。她目前担任IDEXX Laboratories, Inc.和Wolters Kluwer n.v。(两者都是上市公司)的董事会成员,以及Inari Agriculture, Inc.(一家私人控股的生物技术公司)的董事会成员,并曾担任Analogic Corporation的董事会成员。2021年,Vandebroek博士被任命为比利时鲁汶大学荣誉教授。Vandebroek博士是弗兰德斯人工智能研究计划咨询委员会主席,也是电气和电子工程师协会的研究员。她持有KU Leuven, Leuven, Belgium的机电工程学士学位和硕士学位,以及Cornell大学的电气工程博士学位。


Sophie V. Vandebroek,has served as founder and owner of Strategic Vision Ventures, LLC, a technology consulting firm, since 2021. Previously, Dr. Vandebroek was the inaugural visiting scholar at the Massachusetts Institute of Technology School of Engineering for the 2019-2020 academic year; Vice President, Emerging Technology Partnerships for IBM from 2018 to 2019; and Chief Operating Officer - IBM Research from 2017 to 2018. Prior to joining IBM, she was an executive with Xerox Corporation, where her roles included serving as Chief Technology Officer and Corporate Vice President of Xerox Corporation, President of the Xerox Innovation Group, and Chief Engineer. She was also responsible for overseeing Xerox's global research centers, including the Palo Alto Research Center, or PARC Inc. Dr. Vandebroek currently serves on the boards of IDEXX Laboratories, Inc. and Wolters Kluwer N. V., both of which are publicly traded, as well as Inari Agriculture, Inc., a privately held biotechnology company, and formerly served on the board of Analogic Corporation. In 2021, Dr. Vandebroek was appointed an honorary Professor at KU Leuven, Belgium. Dr. Vandebroek is the Chair of the Advisory Committee of the Flanders AI Research Program and a Fellow of the Institute of Electrical & Electronics Engineers. Dr. Vandebroek holds a bachelor's degree and a master's degree in electro-mechanical engineering from KU Leuven, Leuven, Belgium, and a doctoral degree in electrical engineering from Cornell University.
Sophie V. Vandebroek,自2021年起担任Strategic Vision Ventures, LLC(技术咨询公司)的创始人和所有者。此前,Vandebroek博士是麻省理工学院工程学院2019-2020学年的首任访问学者;2018年至2019年担任IBM新兴技术合作伙伴副总裁;2017年至2018年担任IBM研究院首席运营官。在加入IBM之前,她是Xerox Corporation的高管,在那里她的角色包括担任Xerox Corporation的首席技术官和公司副总裁,Xerox Innovation Group总裁和首席工程师。她还负责监督施乐公司的全球研究中心,包括帕洛阿尔托研究中心(PARC Inc.)。她目前担任IDEXX Laboratories, Inc.和Wolters Kluwer n.v。(两者都是上市公司)的董事会成员,以及Inari Agriculture, Inc.(一家私人控股的生物技术公司)的董事会成员,并曾担任Analogic Corporation的董事会成员。2021年,Vandebroek博士被任命为比利时鲁汶大学荣誉教授。Vandebroek博士是弗兰德斯人工智能研究计划咨询委员会主席,也是电气和电子工程师协会的研究员。她持有KU Leuven, Leuven, Belgium的机电工程学士学位和硕士学位,以及Cornell大学的电气工程博士学位。
Sophie V. Vandebroek,has served as founder and owner of Strategic Vision Ventures, LLC, a technology consulting firm, since 2021. Previously, Dr. Vandebroek was the inaugural visiting scholar at the Massachusetts Institute of Technology School of Engineering for the 2019-2020 academic year; Vice President, Emerging Technology Partnerships for IBM from 2018 to 2019; and Chief Operating Officer - IBM Research from 2017 to 2018. Prior to joining IBM, she was an executive with Xerox Corporation, where her roles included serving as Chief Technology Officer and Corporate Vice President of Xerox Corporation, President of the Xerox Innovation Group, and Chief Engineer. She was also responsible for overseeing Xerox's global research centers, including the Palo Alto Research Center, or PARC Inc. Dr. Vandebroek currently serves on the boards of IDEXX Laboratories, Inc. and Wolters Kluwer N. V., both of which are publicly traded, as well as Inari Agriculture, Inc., a privately held biotechnology company, and formerly served on the board of Analogic Corporation. In 2021, Dr. Vandebroek was appointed an honorary Professor at KU Leuven, Belgium. Dr. Vandebroek is the Chair of the Advisory Committee of the Flanders AI Research Program and a Fellow of the Institute of Electrical & Electronics Engineers. Dr. Vandebroek holds a bachelor's degree and a master's degree in electro-mechanical engineering from KU Leuven, Leuven, Belgium, and a doctoral degree in electrical engineering from Cornell University.
Peter Barrett

Peter Barrett,2002年加入早期生命科学风险投资基金Atlas Venture,是生命科学集团的合伙人,曾参与创建多家治疗和药物发现平台公司。此前,他是Celera Genomics的联合创始人、执行副总裁兼首席商务官,该公司于2001年宣布首次成功进行人类基因组测序。在此之前,Barrett博士曾在Perkin-Elmer公司担任多个高级管理职位,最近担任企业规划和业务发展副总裁,在那里他经营着多项业务,并通过一系列许可协议、合作伙伴关系和收购帮助大幅扩展其生命科学产品组合。他目前担任上市公司Synlogic, Inc.的董事长,并且是私人控股的Obsidian Therapeutics,Inc.的董事会成员。Barrett博士还是哈佛商学院的执行研究员,并且是Blavatnik Fellowship项目关键顾问委员会的主席。Barrett博士在洛厄尔技术学院(现称马萨诸塞大学洛厄尔分校)获得化学理学学士学位,并在东北大学获得分析化学博士学位。


Peter Barrett,joined Atlas Venture, an early-stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group, where he has been involved in the creation of several therapeutic and drug discovery platform companies. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics which in 2001 announced the first successful sequencing of the human genome. Prior to that, Dr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development, where he operated several businesses and helped to greatly expand its life sciences portfolio through a series of licensing agreements, partnerships and acquisitions. He currently serves as the Chairman of Synlogic, Inc., which is publicly traded, and is a board member of privately held Obsidian Therapeutics, Inc. Dr. Barrett is also an executive fellow at the Harvard Business School and is the chair of the key advisory board of the Blavatnik Fellowship program. Dr. Barrett previously served on the board of Larimar Therapeutics, Inc., a publicly traded company, until 2023. In addition, Dr. Barrett is a board member of Nucleate, a student run non-profit organization representing the global community of bio-innovators. Dr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his doctoral degree in analytical chemistry from Northeastern University.
Peter Barrett,2002年加入早期生命科学风险投资基金Atlas Venture,是生命科学集团的合伙人,曾参与创建多家治疗和药物发现平台公司。此前,他是Celera Genomics的联合创始人、执行副总裁兼首席商务官,该公司于2001年宣布首次成功进行人类基因组测序。在此之前,Barrett博士曾在Perkin-Elmer公司担任多个高级管理职位,最近担任企业规划和业务发展副总裁,在那里他经营着多项业务,并通过一系列许可协议、合作伙伴关系和收购帮助大幅扩展其生命科学产品组合。他目前担任上市公司Synlogic, Inc.的董事长,并且是私人控股的Obsidian Therapeutics,Inc.的董事会成员。Barrett博士还是哈佛商学院的执行研究员,并且是Blavatnik Fellowship项目关键顾问委员会的主席。Barrett博士在洛厄尔技术学院(现称马萨诸塞大学洛厄尔分校)获得化学理学学士学位,并在东北大学获得分析化学博士学位。
Peter Barrett,joined Atlas Venture, an early-stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group, where he has been involved in the creation of several therapeutic and drug discovery platform companies. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics which in 2001 announced the first successful sequencing of the human genome. Prior to that, Dr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development, where he operated several businesses and helped to greatly expand its life sciences portfolio through a series of licensing agreements, partnerships and acquisitions. He currently serves as the Chairman of Synlogic, Inc., which is publicly traded, and is a board member of privately held Obsidian Therapeutics, Inc. Dr. Barrett is also an executive fellow at the Harvard Business School and is the chair of the key advisory board of the Blavatnik Fellowship program. Dr. Barrett previously served on the board of Larimar Therapeutics, Inc., a publicly traded company, until 2023. In addition, Dr. Barrett is a board member of Nucleate, a student run non-profit organization representing the global community of bio-innovators. Dr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his doctoral degree in analytical chemistry from Northeastern University.
Pascale Witz

Pascale Witz持有Institut National des Sciences Appliquées Lyon的生命科学/分子生物学硕士学位和欧洲工商管理学院(INSEAD)的工商管理硕士学位。她在研究实验室开始她的职业生涯(在1991年移到Becton Dickinson France的营销之前)。她于1996年加入GE Healthcare。在GEHC的职业生涯中,她领导许多业务。她是信息技术的副总裁,六西格玛和质量(Six Sigma and Quality)的副总裁(从2000年到2001年),核医学和PET的总经理(从2002年到2004年),销售&营销服务的副总裁(从2005年到2006年),计算机断层扫描的总经理(从2006年到2007年),法国和美国全球介入业务的副总裁和总经理(从2008年到2009年)。2009年她被任命为医学诊断业务的总裁和首席执行官。她成为Sanofi执行委员会(Executive Committee)的成员,2013年7月被任命到她现在的职位。


Pascale Witz,has served as the President of PWH Advisors, a consultancy firm advising healthcare and investment companies, since founding the firm in 2016. Previously, Ms. Witz served as a Member of the Executive Committee for Sanofi, S. A., most recently as Executive Vice President, Global Diabetes & Cardiovascular, and previously as Executive Vice President, Global Pharma and Consumer Healthcare divisions. Before joining Sanofi, Ms. Witz served as President and Chief Executive Officer of GE's pharmaceutical diagnostics, a $2 billion integrated pharmaceutical business that encompassed research and development through commercialization. Previously Ms. Witz served with GE Healthcare, where she held positions of increasing responsibility in Europe and the United States. Before joining GE Healthcare, Ms. Witz was previously employed with Becton Dickinson Pharmaceutical Systems. Ms. Witz currently serves on the boards of publicly traded companies Fresenius Medical Care AG and Regulus Therapeutics, Inc., as well as several privately held companies. Ms. Witz formerly served on the boards of publicly traded Horizon Therapeutics plc until 2023, Savencia SA until 2018, and Tesaro, Inc. until 2019. Ms. Witz received her Master of Business Administration degree from INSEAD, Fontainebleau, France and her Master of Science degree in biochemistry from the Institut National des Sciences Appliquées, Lyon, France. She was also a doctoral student in molecular biology at the Centre National de la Recherche Scientifique, Strasbourg, France.
Pascale Witz持有Institut National des Sciences Appliquées Lyon的生命科学/分子生物学硕士学位和欧洲工商管理学院(INSEAD)的工商管理硕士学位。她在研究实验室开始她的职业生涯(在1991年移到Becton Dickinson France的营销之前)。她于1996年加入GE Healthcare。在GEHC的职业生涯中,她领导许多业务。她是信息技术的副总裁,六西格玛和质量(Six Sigma and Quality)的副总裁(从2000年到2001年),核医学和PET的总经理(从2002年到2004年),销售&营销服务的副总裁(从2005年到2006年),计算机断层扫描的总经理(从2006年到2007年),法国和美国全球介入业务的副总裁和总经理(从2008年到2009年)。2009年她被任命为医学诊断业务的总裁和首席执行官。她成为Sanofi执行委员会(Executive Committee)的成员,2013年7月被任命到她现在的职位。
Pascale Witz,has served as the President of PWH Advisors, a consultancy firm advising healthcare and investment companies, since founding the firm in 2016. Previously, Ms. Witz served as a Member of the Executive Committee for Sanofi, S. A., most recently as Executive Vice President, Global Diabetes & Cardiovascular, and previously as Executive Vice President, Global Pharma and Consumer Healthcare divisions. Before joining Sanofi, Ms. Witz served as President and Chief Executive Officer of GE's pharmaceutical diagnostics, a $2 billion integrated pharmaceutical business that encompassed research and development through commercialization. Previously Ms. Witz served with GE Healthcare, where she held positions of increasing responsibility in Europe and the United States. Before joining GE Healthcare, Ms. Witz was previously employed with Becton Dickinson Pharmaceutical Systems. Ms. Witz currently serves on the boards of publicly traded companies Fresenius Medical Care AG and Regulus Therapeutics, Inc., as well as several privately held companies. Ms. Witz formerly served on the boards of publicly traded Horizon Therapeutics plc until 2023, Savencia SA until 2018, and Tesaro, Inc. until 2019. Ms. Witz received her Master of Business Administration degree from INSEAD, Fontainebleau, France and her Master of Science degree in biochemistry from the Institut National des Sciences Appliquées, Lyon, France. She was also a doctoral student in molecular biology at the Centre National de la Recherche Scientifique, Strasbourg, France.

高管简历

中英对照 |  中文 |  英文
Prahlad Singh

Prahlad Singh于2019年12月30日当选为PerkinElmer的总裁兼首席执行官,并于2019年间被任命为Perkinellmer股份有限公司的董事会成员。此前,Singh博士自2019年1月起担任Perkinellmer 的总裁和首席运营官。Singh博士于2014年5月加入Perkineller,担任股份有限公司诊断业务的总裁。他于2016年9月当选为高级副总裁,并于2018年3月当选为执行副总裁。在加入PerkinElmer之前,Singh博士于2012年至2014年担任GE Healthcare女性健康业务总经理,负责其乳房X光摄影和骨密度测量业务。在此之前,Singh博士曾在GE Healthcare和Philips Healthcar担任战略、业务发展和并购方面的高级执行官。在其职业生涯早期,他曾在杜邦制药公司担任领导职务,并在随后的百时美施贵宝医疗成像公司(Bristol Myers Squibb Medical Imaging)担任领导职务。该公司负责管理亚太和中东地区。Singh 博士拥有密苏里哥伦比亚大学化学博士学位和东北大学工商管理硕士学位。他的研究工作已获得多项专利,并在同行评议的期刊上发表。


Prahlad Singh,is currently the President and Chief Executive Officer of Revvity, Inc. (which was previously affiliated with PerkinElmer, Inc.). He was promoted to President and Chief Executive Officer effective December 30, 2019 and was appointed to its Board of Directors in August 2019. Prior to his current role, he held various senior executive operating positions within PerkinElmer. Prior to joining PerkinElmer in 2014, Mr. Singh was a General Manager at GE Healthcare, and before that, Mr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently at Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East regions.In addition to his public board service, Mr. Singh also serves on the Board of the Analytical, Life Science & Diagnostics Association.Mr. Singh holds a BS degree from Wilson College, Mumbai, India, a PhD in chemistry from the University of Missouri-Columbia and an MBA from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals.
Prahlad Singh于2019年12月30日当选为PerkinElmer的总裁兼首席执行官,并于2019年间被任命为Perkinellmer股份有限公司的董事会成员。此前,Singh博士自2019年1月起担任Perkinellmer 的总裁和首席运营官。Singh博士于2014年5月加入Perkineller,担任股份有限公司诊断业务的总裁。他于2016年9月当选为高级副总裁,并于2018年3月当选为执行副总裁。在加入PerkinElmer之前,Singh博士于2012年至2014年担任GE Healthcare女性健康业务总经理,负责其乳房X光摄影和骨密度测量业务。在此之前,Singh博士曾在GE Healthcare和Philips Healthcar担任战略、业务发展和并购方面的高级执行官。在其职业生涯早期,他曾在杜邦制药公司担任领导职务,并在随后的百时美施贵宝医疗成像公司(Bristol Myers Squibb Medical Imaging)担任领导职务。该公司负责管理亚太和中东地区。Singh 博士拥有密苏里哥伦比亚大学化学博士学位和东北大学工商管理硕士学位。他的研究工作已获得多项专利,并在同行评议的期刊上发表。
Prahlad Singh,is currently the President and Chief Executive Officer of Revvity, Inc. (which was previously affiliated with PerkinElmer, Inc.). He was promoted to President and Chief Executive Officer effective December 30, 2019 and was appointed to its Board of Directors in August 2019. Prior to his current role, he held various senior executive operating positions within PerkinElmer. Prior to joining PerkinElmer in 2014, Mr. Singh was a General Manager at GE Healthcare, and before that, Mr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently at Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East regions.In addition to his public board service, Mr. Singh also serves on the Board of the Analytical, Life Science & Diagnostics Association.Mr. Singh holds a BS degree from Wilson College, Mumbai, India, a PhD in chemistry from the University of Missouri-Columbia and an MBA from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals.
Tajinder Vohra

Tajinder Vohra于2015年10月加入PerkinElmer,担任全球运营副总裁,并于2018年1月被任命为高级副总裁。他负责PerkinElmer的所有全球运营,包括制造,供应链,客户服务和分销。在加入PerkinElmer之前,Vohra先生于2011年至2015年在ABB担任国家运营负责人,负责印度范围内的业务以及印度,中东和非洲的供应链。在2011年之前,Vohra先生是Genpact的高级副总裁,管理供应链和IT业务,并在GE Healthcare担任过多个全球管理运营职位。 Vohra先生拥有德里大学的机械工程学士学位,阿拉巴马大学的工业工程硕士学位和利哈伊大学的制造工程硕士学位。 Vohra先生是经过认证的6西格玛黑带,并在日本的Shinjijitsu培训学院接受了精益生产的培训。


Tajinder Vohra,joined Revvity in October 2015 as Vice President of Global Operations and was appointed Senior Vice President, Global Operations in January 2018. He oversees all of Revvity's global operations, including manufacturing, supply chain, customer care and distribution. Prior to joining Revvity, Mr. Vohra served at ABB as a Country Operations Leader, where he was responsible for India-wide operations and Supply Chains for India, Middle East and Africa. Previously, Mr. Vohra was a Senior Vice President with Genpact, managing Supply Chain and IT businesses, and held a number of global management operational positions with GE Healthcare. Mr. Vohra received his Bachelor's degree in Mechanical Engineering from the University of Delhi, Master's degree in Industrial Engineering from the University of Alabama and Master's degree in Manufacturing Engineering from Lehigh University. Mr. Vohra is a certified Six Sigma Black Belt and was trained in lean manufacturing at the Shingijitsu Training Institute in Japan.
Tajinder Vohra于2015年10月加入PerkinElmer,担任全球运营副总裁,并于2018年1月被任命为高级副总裁。他负责PerkinElmer的所有全球运营,包括制造,供应链,客户服务和分销。在加入PerkinElmer之前,Vohra先生于2011年至2015年在ABB担任国家运营负责人,负责印度范围内的业务以及印度,中东和非洲的供应链。在2011年之前,Vohra先生是Genpact的高级副总裁,管理供应链和IT业务,并在GE Healthcare担任过多个全球管理运营职位。 Vohra先生拥有德里大学的机械工程学士学位,阿拉巴马大学的工业工程硕士学位和利哈伊大学的制造工程硕士学位。 Vohra先生是经过认证的6西格玛黑带,并在日本的Shinjijitsu培训学院接受了精益生产的培训。
Tajinder Vohra,joined Revvity in October 2015 as Vice President of Global Operations and was appointed Senior Vice President, Global Operations in January 2018. He oversees all of Revvity's global operations, including manufacturing, supply chain, customer care and distribution. Prior to joining Revvity, Mr. Vohra served at ABB as a Country Operations Leader, where he was responsible for India-wide operations and Supply Chains for India, Middle East and Africa. Previously, Mr. Vohra was a Senior Vice President with Genpact, managing Supply Chain and IT businesses, and held a number of global management operational positions with GE Healthcare. Mr. Vohra received his Bachelor's degree in Mechanical Engineering from the University of Delhi, Master's degree in Industrial Engineering from the University of Alabama and Master's degree in Manufacturing Engineering from Lehigh University. Mr. Vohra is a certified Six Sigma Black Belt and was trained in lean manufacturing at the Shingijitsu Training Institute in Japan.
Miriame Victor

Miriame Victor于2014年10月加入PerkinElmer,担任欧洲诊断业务的销售主管,最近一次担任EMEAI的副总裁和总经理,之后于2021年1月被任命为高级副总裁和首席商务官。担任这一职务时,她负责监督PerkinElmer在所有业务中的产品商业化工作,最近成功地将诊断和发现与分析解决方案业务整合到一个统一的商业组织中。在加入Perkinlemer之前,Victor女士曾在MSD和诺华制药行业以及GE Healthcare医疗器械行业担任过多个商业领导职位。Victor女士拥有开罗大学药学和药学学士学位,并获得阿拉伯科学、技术和海运学院工商管理硕士学位。


Miriame Victor,joined Revvity in October 2014 as Sales Leader for the Diagnostics business in Europe and most recently served as Vice President and General Manager for EMEAI, prior to being appointed Senior Vice President and Chief Commercial Officer in January 2021. In that role, she oversees Revvity's product commercialization efforts across all businesses, having previously completed the successful consolidation of the Diagnostics business with other businesses into one unified commercial organization. Prior to joining Revvity, Ms. Victor held various commercial leadership positions in the pharmaceutical industry with MSD and Novartis, and in the medical device industry with GE Healthcare. Ms. Victor holds a Bachelor of Science degree in pharmacy and pharmaceutical sciences from Cairo University and earned her Master of Business Administration from Arab Academy for Science, Technology and Maritime Transport.
Miriame Victor于2014年10月加入PerkinElmer,担任欧洲诊断业务的销售主管,最近一次担任EMEAI的副总裁和总经理,之后于2021年1月被任命为高级副总裁和首席商务官。担任这一职务时,她负责监督PerkinElmer在所有业务中的产品商业化工作,最近成功地将诊断和发现与分析解决方案业务整合到一个统一的商业组织中。在加入Perkinlemer之前,Victor女士曾在MSD和诺华制药行业以及GE Healthcare医疗器械行业担任过多个商业领导职位。Victor女士拥有开罗大学药学和药学学士学位,并获得阿拉伯科学、技术和海运学院工商管理硕士学位。
Miriame Victor,joined Revvity in October 2014 as Sales Leader for the Diagnostics business in Europe and most recently served as Vice President and General Manager for EMEAI, prior to being appointed Senior Vice President and Chief Commercial Officer in January 2021. In that role, she oversees Revvity's product commercialization efforts across all businesses, having previously completed the successful consolidation of the Diagnostics business with other businesses into one unified commercial organization. Prior to joining Revvity, Ms. Victor held various commercial leadership positions in the pharmaceutical industry with MSD and Novartis, and in the medical device industry with GE Healthcare. Ms. Victor holds a Bachelor of Science degree in pharmacy and pharmaceutical sciences from Cairo University and earned her Master of Business Administration from Arab Academy for Science, Technology and Maritime Transport.
Maxwell Krakowiak

Maxwell Krakowiak,于2022年8月被任命为PerkinElmer的高级副总裁兼首席财务官,此前他最近担任PerkinElmer, Inc.的董事。公司金融副总裁,专注于通过人员、流程和自动化推动全球金融转型。Krakowiak先生于2018年10月加入PerkinElmer, Inc.担任高级副总裁兼首席财务官曾担任多个财务领导职务,范围和职责越来越大,包括监督财务规划和分析、商业金融和业务发展。加入PerkinElmer之前,Krakowiak先生在通用电气公司(“GE”)工作了七年,最近担任执行审计经理(2018年1月至2018年10月),在GE的全球业务中从事财务审计和卓越运营项目。在GE任职期间,他在GE的企业审计人员和财务管理项目中担任过许多领导角色。Krakowiak先生持有Fordham University的金融学学士学位。


Maxwell Krakowiak,was appointed Senior Vice President and Chief Financial Officer of Revvity in August 2022 after having most recently served as Revvity, Inc. Vice President, Corporate Finance, focusing on driving global finance transformation through people, process and automation. Mr. Krakowiak joined Revvity in October 2018, and prior to being appointed as Revvity, Inc. Senior Vice President and Chief Financial Officer held several financial leadership positions of increasing scope and responsibilities, including oversight of financial planning and analysis, commercial finance and business development. Prior to joining Revvity, Mr. Krakowiak worked for General Electric Company ("GE") for seven years, most recently as Executive Audit Manager, working globally across GE's businesses on financial audits and operational excellence projects. During his tenure at GE, he served in a number of progressively responsible leadership roles across GE's Corporate Audit Staff and Financial Management leadership programs. Mr. Krakowiak holds a Bachelor of Science degree in finance from Fordham University.
Maxwell Krakowiak,于2022年8月被任命为PerkinElmer的高级副总裁兼首席财务官,此前他最近担任PerkinElmer, Inc.的董事。公司金融副总裁,专注于通过人员、流程和自动化推动全球金融转型。Krakowiak先生于2018年10月加入PerkinElmer, Inc.担任高级副总裁兼首席财务官曾担任多个财务领导职务,范围和职责越来越大,包括监督财务规划和分析、商业金融和业务发展。加入PerkinElmer之前,Krakowiak先生在通用电气公司(“GE”)工作了七年,最近担任执行审计经理(2018年1月至2018年10月),在GE的全球业务中从事财务审计和卓越运营项目。在GE任职期间,他在GE的企业审计人员和财务管理项目中担任过许多领导角色。Krakowiak先生持有Fordham University的金融学学士学位。
Maxwell Krakowiak,was appointed Senior Vice President and Chief Financial Officer of Revvity in August 2022 after having most recently served as Revvity, Inc. Vice President, Corporate Finance, focusing on driving global finance transformation through people, process and automation. Mr. Krakowiak joined Revvity in October 2018, and prior to being appointed as Revvity, Inc. Senior Vice President and Chief Financial Officer held several financial leadership positions of increasing scope and responsibilities, including oversight of financial planning and analysis, commercial finance and business development. Prior to joining Revvity, Mr. Krakowiak worked for General Electric Company ("GE") for seven years, most recently as Executive Audit Manager, working globally across GE's businesses on financial audits and operational excellence projects. During his tenure at GE, he served in a number of progressively responsible leadership roles across GE's Corporate Audit Staff and Financial Management leadership programs. Mr. Krakowiak holds a Bachelor of Science degree in finance from Fordham University.
Anita Gonzales

Anita Gonzales于2023年5月被任命为Revvity,Inc.副总裁兼财务总监,并于2021年3月加入Revvity,担任整合和控制计划高级总监。在加入Revvity之前,Gonzales夫人曾在通用电气公司(“GE”)工作了十年。在GE任职期间,Gonzales女士于2016年至2021年担任审计和咨询实践公司部门总监,负责公司审计人员的技术会计和审计标准。在此之前,冈萨雷斯夫人在通用航空担任过包括全球控制器-商用发动机在内的高管职务。在她职业生涯的早期,她在普华永道担任过越来越多的职责,直至高级经理。Gonzales女士拥有得克萨斯大学奥斯汀分校公共会计硕士和工商管理学士学位,是一名注册会计师。


Anita Gonzales,was appointed Vice President and Controller in May 2023, having joined Revvity as Senior Director of Integration and Controllership Initiatives in March 2021. Prior to joining Revvity, Mrs. Gonzales was at General Electric Company ("GE") for ten years. During her tenure at GE, Mrs. Gonzales was Director of Audit and Advisory Practices Corporate division from 2016 to 2021, with responsibility for technical accounting and auditing standards of the Corporate Audit Staff. Before that, Mrs. Gonzales held executive roles at GE Aviation including Global Controller- Commercial Engines. Earlier in her career, she held roles of increasing responsibility, up to Senior Manager, at PricewaterhouseCoopers. Mrs. Gonzales holds Master of Public Accounting and Bachelor of Business Administration degrees from the University of Texas at Austin and is a Certified Public Accountant.
Anita Gonzales于2023年5月被任命为Revvity,Inc.副总裁兼财务总监,并于2021年3月加入Revvity,担任整合和控制计划高级总监。在加入Revvity之前,Gonzales夫人曾在通用电气公司(“GE”)工作了十年。在GE任职期间,Gonzales女士于2016年至2021年担任审计和咨询实践公司部门总监,负责公司审计人员的技术会计和审计标准。在此之前,冈萨雷斯夫人在通用航空担任过包括全球控制器-商用发动机在内的高管职务。在她职业生涯的早期,她在普华永道担任过越来越多的职责,直至高级经理。Gonzales女士拥有得克萨斯大学奥斯汀分校公共会计硕士和工商管理学士学位,是一名注册会计师。
Anita Gonzales,was appointed Vice President and Controller in May 2023, having joined Revvity as Senior Director of Integration and Controllership Initiatives in March 2021. Prior to joining Revvity, Mrs. Gonzales was at General Electric Company ("GE") for ten years. During her tenure at GE, Mrs. Gonzales was Director of Audit and Advisory Practices Corporate division from 2016 to 2021, with responsibility for technical accounting and auditing standards of the Corporate Audit Staff. Before that, Mrs. Gonzales held executive roles at GE Aviation including Global Controller- Commercial Engines. Earlier in her career, she held roles of increasing responsibility, up to Senior Manager, at PricewaterhouseCoopers. Mrs. Gonzales holds Master of Public Accounting and Bachelor of Business Administration degrees from the University of Texas at Austin and is a Certified Public Accountant.
Joel S. Goldberg

Joel S. Goldberg目前担任Perkinelmer, Inc.的高级副总裁、行政、总法律顾问和秘书,并于2008年7月加入Perkinelmer, Inc.高级副总裁兼总法律顾问兼秘书。在加入Perkinelmer,Inc.之前,Goldberg先生在Millennium Pharmaceuticals,Inc.工作了七年,最近担任该公司副总裁、首席合规官和秘书。在千禧年的七年中,他专注于并购、战略联盟、投资和融资交易、证券和医疗保健相关合规以及就业法等领域。此前,他是Edwards&Angell律师事务所的合伙人。Goldberg先生毕业于东北大学法学院,同时持有东北大学工商管理硕士学位。他在威斯康星大学麦迪逊分校完成了本科学位。


Joel S. Goldberg,currently serves as Senior Vice President, Administration, General Counsel and Secretary, having joined as Revvity, Inc. Senior Vice President, General Counsel and Secretary in July 2008. Prior to joining Revvity, Inc. , Mr. Goldberg spent seven years at Millennium Pharmaceuticals, Inc., where he most recently served as Vice President, Chief Compliance Officer and Secretary. During his seven years with Millennium, he focused in the areas of mergers and acquisitions, strategic alliances, investment and financing transactions, securities and healthcare related compliance, and employment law. Previously, he was an associate of the law firm Edwards & Angell, LLP. Mr. Goldberg graduated from the Northeastern University School of Law and also holds a Master of Business Administration from Northeastern University. He completed his undergraduate degree at the University of Wisconsin-Madison.
Joel S. Goldberg目前担任Perkinelmer, Inc.的高级副总裁、行政、总法律顾问和秘书,并于2008年7月加入Perkinelmer, Inc.高级副总裁兼总法律顾问兼秘书。在加入Perkinelmer,Inc.之前,Goldberg先生在Millennium Pharmaceuticals,Inc.工作了七年,最近担任该公司副总裁、首席合规官和秘书。在千禧年的七年中,他专注于并购、战略联盟、投资和融资交易、证券和医疗保健相关合规以及就业法等领域。此前,他是Edwards&Angell律师事务所的合伙人。Goldberg先生毕业于东北大学法学院,同时持有东北大学工商管理硕士学位。他在威斯康星大学麦迪逊分校完成了本科学位。
Joel S. Goldberg,currently serves as Senior Vice President, Administration, General Counsel and Secretary, having joined as Revvity, Inc. Senior Vice President, General Counsel and Secretary in July 2008. Prior to joining Revvity, Inc. , Mr. Goldberg spent seven years at Millennium Pharmaceuticals, Inc., where he most recently served as Vice President, Chief Compliance Officer and Secretary. During his seven years with Millennium, he focused in the areas of mergers and acquisitions, strategic alliances, investment and financing transactions, securities and healthcare related compliance, and employment law. Previously, he was an associate of the law firm Edwards & Angell, LLP. Mr. Goldberg graduated from the Northeastern University School of Law and also holds a Master of Business Administration from Northeastern University. He completed his undergraduate degree at the University of Wisconsin-Madison.